deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT00923247

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC)

Sponsor: National Cancer Institute (NCI)

Conditions Medullary Thyroid Carcinoma
Interventions Bortezomib Vandetanib
Updated 12 times since 2017 Last updated: Nov 5, 2018 Started: Feb 19, 2009 Primary completion: Apr 1, 2016 Completion: Dec 9, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated due to slow accrual,primary endpoint reached \& investigator left NIH.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

This PHASE1/PHASE2 trial investigates Medullary Thyroid Carcinoma and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 12 recorded versions since 2009 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshotActive Not Recruiting~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotCompleted~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshotTerminated~Dec 2018 – ~Jan 2021 · 25 months · monthly snapshotTerminated~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshotTerminated~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshotTerminated~Mar 2022 – ~Dec 2022 · 9 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 23 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE1_PHASE2

  5. Mar 2022 — Dec 2022 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 7 earlier versions

  1. Jan 2022 — Mar 2022 [monthly]

    Terminated PHASE1_PHASE2

  2. Jan 2021 — Jan 2022 [monthly]

    Terminated PHASE1_PHASE2

  3. Dec 2018 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  4. Jun 2018 — Dec 2018 [monthly]

    Terminated PHASE1_PHASE2

    Status: Completed → Terminated

  5. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  6. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations